Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
30.00
+0.68 (2.32%)
At close: Oct 7, 2026, 4:00 PM EDT
30.01
0.00 (0.02%)
After-hours: Oct 7, 2026, 7:30 PM EDT
LKFT Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, LKFT stock has a consensus rating of "Hold" and an average price target of $30.34. The average 1-year stock price forecast is 1.13% higher than the current stock price, while the lowest is $21.39 (-28.70%) and the highest is $44.28 (+47.60%).
Price Target: $30.34 (+1.13%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for LKFT stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 3 | 3 | 3 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Total | 3 | 4 | 4 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Reiterates $26 | Hold | Reiterates | $26 | -13.33% | Oct 5, 2026 |
| RBC Capital | RBC Capital | Buy Upgrades $26 → $45 | Buy | Upgrades | $26 → $45 | +50.00% | Sep 23, 2026 |
Financial Forecast
Revenue This Year
117.22M
from 1.11B
Decreased by -89.46%
Revenue Next Year
41.90M
from 117.22M
Decreased by -64.26%
EPS This Year
-4.25
from 10.21
EPS Next Year
-4.95
from -4.25
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.